Iberdomide
Iberdomide (CC-220) is an orally active and potent cereblon (CRBN) E3 ligase modulator (CELMoD) with an IC50 of ~150 nM for cereblon-binding affinity. Iberdomide, a derivative of Thalidomide , has antitumor and immunostimulatory activities[1][2].
Product Specifications
CAS Number
1323403-33-3
Product Name Alternative
CC-220
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Apoptosis; Ligands for E3 Ligase; Molecular Glues
Type
Reference compound
Related Pathways
Apoptosis; PROTAC
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cancer
Assay Protocol
https://www.medchemexpress.com/Iberdomide.html
Purity
99.54
Solubility
DMSO : 175 mg/mL (ultrasonic)
Smiles
O=C([C@@H](N(CC1=C2C=CC=C1OCC3=CC=C(CN4CCOCC4)C=C3)C2=O)CC5)NC5=O
Molecular Formula
C25H27N3O5
Molecular Weight
449.50
Precautions
H315, H319, H335
References & Citations
[1]Chad C Bjorklund, et al. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia. 2020 Apr;34 (4) :1197-1201.|[2]Erin W Meermeier, et al. Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. Blood Cancer Discov. 2021 Jul;2 (4) :354-369.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
Cereblon
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
